30 results about "Respiratory syncytial virus RS" patented technology

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

The invention belongs to the field of biotechnology, and particularly relates to a respiratory syncytial virus (RSV) virus-like particle (VLPs) subunit vaccine as well as a preparation method and application thereof. The component of the vaccine is chimeric antigen protein which is fusion-expressed together with neutral antigenic epitope of an RSVG protein or simultaneously with the antigenic epitope of T cells of an M2 protein by taking hepatitis B virus core protein as a carrier. The high-purity antigen component is prepared by efficiently expressing antigen protein in escherichia coli and then performing in-vitro purification, degeneration and renaturation and self assembling into virus-like particles (VLPs). The RSVG protein contained in the VLPs and the antigenic epitope of the T cells of the M2 protein are simultaneously expressed, so that the capability of the vaccine for introducing specific immunity response and anti-RSV infection immunity protection can be enhanced, the balanced Th1 / Th2 immunity response can be induced and the RSV vaccine is prevented from enhancing the incidence of diseases. Animals are immunized and inoculated with VLPs vaccines to induce organisms to generate high-level RSV neutral antigens, enhanced Th1 cell factor level and effective protection on RSV attack infection.

The invention provides a human respiratory syncytial virus antigen detection method based on magnetic separating and quantum dot labeling. The method comprises the steps that 1, immune nano magnetic beads resisting a human respiratory syncytial virus are prepared; 2, quantum-dot-labeled nano-probes resisting the human respiratory syncytial virus are prepared; 3, after a sample to be detected is dissolved with a sample processing solution, the immune nano magnetic beads resisting the human respiratory syncytial virus are added in a dissolved solution, magnetic separating is performed after full mixing and reacting are performed, washing is performed with a PBST buffer solution, the quantum-dot-labeled nano-probes resisting the human respiratory syncytial virus are added in obtained precipitates, magnetic separating is performed after reacting is performed, and after washing is performed with the PBST buffer solution, a fluorescence value is detected with a fluorescence microplate reader. Accordingly, the accurate, rapid and high-sensitivity method for detecting the human respiratory syncytial virus is established, and the very high practical value in the aspects such as clinical diagnosis, etiology identification and epidemiological investigation of the human respiratory syncytial virus is achieved.

The invention provides an immune detection reagent for detecting respiratory syncytial virus and a corresponding reagent box. The immune detection reagent comprises anti-respiratory syncytial virus monoclonal antibody 1 as peridium antibody, anti-respiratory syncytial virus monoclonal antibody 2 as biotin labeling antibody and avidin-HRP (horseradish peroxidase). The invention also provides a method for detecting the respiratory syncytial virus by applying the immune detection reagent or the reagent box. The method has relatively high sensitivity and specificity and is easy to clinically use.

The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory synctial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and / or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

The invention relates to respiratory syncytial virus resistance human immune globulin and a preparation method thereof. The titer of the respiratory syncytial virus neutralizing antibody is larger than or equal to 1:900. The preparation method includes the steps of firstly, screening out privilege plasma with titer of the respiratory syncytial virus neutralizing antibody not lower than 1:200; secondly, mixing screened-out efficient privilege plasma; thirdly, separating the mixed plasma through a low-temperature ethyl alcohol filter press method, purifying and separating out a immune globulin component II through the combination with the ion-exchange column chromatography method, and obtaining immune globulin with the purity of 98-100% through filtration, chromatography, ultrafiltration, preparation, low-pH incubation virus inactivation, nano-membrane filtration virus removal and subpackaging. The titer, purity and recycling rate of the respiratory syncytial virus resistance human immune globulin obtained through the preparation and production method are high, treatment can be conducted for the respiratory syncytial virus, and the respiratory syncytial virus resistance human immune globulin and the preparation method have advantages of being safe, effective and the like.

The present invention relates to the field of medicine and immunology, and specifically discloses a neutralizing antibody against respiratory syncytial viruses and an application thereof. The neutralizing antibody comprises a heavy chain variable region of VH CDR1, VH CDR2 and VH CDR3 and a light chain variable region (or named as a variable light chain domain) of VL CDR1, VL CDR2 and VL CDR3; wherein amino acid sequences of the VH CDR1, VH CDR2 and VH CDR3 in the heavy chain variable region are shown in SEQ ID NO.1, 2 and 3, the amino acid sequences of the VL CDR1, VL CDR2 and VL CDR3 in thelight chain variable region are shown in SEQ ID NO.4, 5 and 6. Based on research results, the present invention also provides a nucleic acid molecule encoding the neutralizing antibody, and applications of the neutralizing antibody in preparing a pre-fusion protein product specifically binding the respiratory syncytial viruses, preparing respiratory syncytial virus vaccines, etc.

The invention discloses a combined detection kit and detection method for viruses associated with respiratory infection nucleic acid, which have the advantages of high specificity, high sensitivity, simple operation, clear result and high reliability, and can be used for qualitative identification and detection of influenza A virus, influenza B virus and respiratory syncytial virus.

The invention discloses a respiratory syncytial virus kit and a detection method thereof, belonging to the technical field of enzyme immunoassay. According to the respiratory syncytial virus kit, the pharyngeal of a child is wiped by adopting a throat swab, nasopharyngeal secretions of the throat swab are dissolved by an ambroxol hydrochloride medicine, nasopharyngeal epithelial cells as sediments are added in 2.0ml of a phosphate buffer solution containing 1.0 percent (V / V)Triton X-100 after being centrifuged at a high speed, stand for 30min, and are violently oscillated so that respiratory syncytial viruses fall off from the nasopharyngeal epithelial cells, a dissolved solution is taken to be added on a respiratory syncytial virus detection ELISA (Enzyme Linked Immunosorbent Assay) plate, the respiratory syncytial viruses are detected by adopting an ELISA method, warm bath and washing are carried out, a biotinylated respiratory syncytial virus antibody is added, streptavidin is coupled with a streptavidinbiotin peroxidase complex, and a substrate liquid is added, thus a result is read. The detection method is simple to operate, is rapid, sensitive and accurate, and is low in cost, is suitable for detecting the infection of nasopharyngeal epithelial cells by the respiratory syncytial viruses, and can be used as an important inspection index of infecting the respiratory syncytial viruses by the child.

The invention provides a method for preparing a monoclonal antibody to a respiratory syncytial virus. According to the method for preparing the monoclonal antibody to the respiratory syncytial virus provided by the invention, memory B cells are separated from peripheral blood of a patient who is infected with and recovered from the respiratory syncytial virus recently to further determine genes of a heavy chain variable region and a light chain variable region to express the antibody; murine typhia competent cell VNP20009 is utilized to directly transfect a 293T cell and enable expression of the monoclonal antibody to the respiratory syncytial virus in vitro; neutralization capacity and killing competence of the monoclonal antibody to the respiratory syncytial virus is evaluated after appraisal, so as to screen high-efficiency and scale production-available monoclonal antibodies to the respiratory syncytial virus. According to the method for preparing the monoclonal antibody to the respiratory syncytial virus provided by the invention, as the murine typhia competent cell VNP20009 is utilized to directly transfect the 293T cell, compared with the conventional methods, not only time is saved, but also the application a lot of transfection reagent can be avoided. As transfection of exogenous plasmids to an expression system is a key link of in-vitro expression of the monoclonal antibody, the invention provides a strong support to industrialized application of the technology.

The invention discloses a detecting method for a respiratory syncytial virus, which includes using an endometrial adenocarcinoma cell line JEC as a respiratory syncytial virus separating tool and then detecting the virus by an indirect immunofluorescence method. The detecting method can be used for visually judging whether a collected specimen contains the RSV (respiratory syncytial virus) or not, and is simple, fine in repeatability, high in sensitivity and low in cost.

The invention discloses a molecular marker in blood serving as a diagnosis index of respiratory syncytial virus infection. The molecular marker in blood is TYMS. Experiments prove that the content ofTYMS gene and TYMS protein in the blood of people infected with respiratory syncytial virus obviously increases compared with that of normal people. Due to the expression difference between TYMS geneand TYMS protein, the content increase can serve as an index for distinguishing the people infected with respiratory syncytial virus from the non-infected people. Compared with traditional virus antibody detection method and virus antigen detection method, the non-virus index in the blood is adopted for virus detection by the invention, and high-sensitivity detection can be realized.

The invention provides a fully-humanized monoclonal antibody RSVG71 or RSVG78 specifically combined with adhesion protein (G) of RSV (respiratory syncytial virus) and discloses encoded nucleic acid of the fully-humanized monoclonal antibody, a carrier or a host cell containing the fully-humanized monoclonal antibody and a preparation method of the fully-humanized monoclonal antibody. The invention further discloses an application of the RSV-resistant fully-humanized monoclonal antibody RSVG71 or RSVG78 in prevention and treatment of RSV related diseases and in detection of RSV.

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and / or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind the fusion (F) protein of respiratory syncytial virus (RSV). Also provided herein are methods for preventing, treating and diagnosing viral infection and / or treating one or more symptoms of RSV-mediated disease. Also provided herein are methods of producing antibodies that immunospecifically bind RSV F protein.

The invention relates to an application of Trichiconins C to preparation of respiratory syncytial virus (RSV) resistant drugs. The compound Trichiconins C is prepared into tablets and capsules. The defect that the RSV can not be completely, directly and effectively killed by existing treatment methods is overcome. Trichiconins C has unexpected strong RSV inhibiting activity and does not have the possibility that other compounds give any enlightenment. Experiments prove that Trichiconins C has outstanding inhibiting effects on the RSV, is used for inhibiting the RSV from having the cytopathic effect (CPE) in the HEK293 cell and has IC50 of 2<-10.49> and TI of 278.23; therefore Trichiconins C has prominent substantive characteristics and obviously has outstanding progress when being used for controlling the RSV.

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.

The invention discloses an attenuated strain KM516-AS of respiratory syncytial virus. The attenuated strain is preserved in China Center for Type Culture Collection, with a preservation number CCTCCNO:V201344. The attenuated strain is cultured in vitro and then obtained and purified, so as to produce an attenuated vaccine of the respiratory syncytial virus. After animal is immunized by the vaccine, and the animal obtains good immunogenicity, protectiveness and security.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind the fusion (F) protein of respiratory syncytial virus (RSV). Also provided are methods for preventing, treating and diagnosing viral infections and / or treating one or more symptoms of RSV-mediated disease. Also provided are methods of producing antibodies that immunospecifically bind RSV F protein.

The invention provides an immune detection reagent for detecting respiratory syncytial virus and a corresponding reagent box. The immune detection reagent comprises anti-respiratory syncytial virus monoclonal antibody 1 as peridium antibody, anti-respiratory syncytial virus monoclonal antibody 2 as biotin labeling antibody and avidin-HRP (horseradish peroxidase). The invention also provides a method for detecting the respiratory syncytial virus by applying the immune detection reagent or the reagent box. The method has relatively high sensitivity and specificity and is easy to clinically use.

The invention discloses a compound for treating respiratory syncytial virus infection, a preparation method and application thereof. The compound is a chemical analogue of cyclopamine, which has the property of inhibiting the replication of respiratory syncytial virus, but does not have the property of inhibiting Hedgehog signaling pathway. The preparation method synthesizes the chemical analogs of the cyclopamine through pharmaceutical chemistry, and screens the analogs through two parallel in vitro tests. The compound can be used to treat respiratory virus infection, paramyxovirus infection, respiratory syncytial virus infection, bronchiolitis caused by respiratory syncytial virus, pneumonia caused by respiratory syncytial virus, otitis media caused by respiratory syncytial virus, It does not have the toxic and side effects of causing fetal malformation, overcomes the teratogenic properties of cyclopamine, and fills in the blank of drugs for treating respiratory syncytial virus infection, especially pediatric drugs.

The invention discloses a nucleic acid detection kit for rapidly detecting respiratory syncytial viruses A and B and an application of the nucleic acid detection kit. The kit comprises the following steps: a nucleic acid amplification reaction liquid, enzyme mixed liquor, a reaction liquid of respiratory syncytial virus A / B, positive control and blank control. According to the nucleic acid detection kit disclosed by the invention, the defects that the nucleic acid detection kit for the respiratory syncytial viruses A and B in the prior art is poor in specificity, relatively low in sensitivity and the like are overcome. The nucleic acid detection kit for the respiratory syncytial viruses A and B disclosed by the invention has the advantages of being high in flux, simple and convenient to operate, high in repeatability, fast and objective in detection result, and has a great application prospect in the aspects such as clinical diagnosis of the respiratory syncytial viruses A and B and disease surveillance.

The invention discloses a molecular marker for child respiratory syncytial virus infection and application of the molecular marker. According to the invention, up-regulated expression of H2AFJ and RGL4 in child patients with the child respiratory syncytial virus infection is found for the first time; by detecting the expression level of the H2AFJ and the RGL4, whether a subject is suffered from respiratory syncytial virus infection diseases or not can be judged.

The invention provides a complete humanized monoclonal antibody RSVG78 specifically binding attachment (G) protein of respiratory syncytial virus (RSV), and discloses coded nucleic acid thereof, vector or host cell containing the complete humanized monoclonal antibi RSV78 and a preparation method thereof. The invention further discloses application of complete humanized anti-RSV monoclonal antibody RSVG78 in prevention and treatment of RSV related diseases and application thereof in RSV detection.

Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.